BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 23032723)

  • 1. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
    Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
    Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
    Kjeldsen E
    Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
    J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
    Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
    Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
    Kuiper R; van Duin M; van Vliet MH; Broijl A; van der Holt B; El Jarari L; van Beers EH; Mulligan G; Avet-Loiseau H; Gregory WM; Morgan G; Goldschmidt H; Lokhorst HM; Sonneveld P
    Blood; 2015 Oct; 126(17):1996-2004. PubMed ID: 26330243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
    Sagaster V; Kaufmann H; Odelga V; Ackermann J; Gisslinger H; Rabitsch W; Zojer N; Ludwig H; Nösslinger T; Zielinski C; Drach J
    Eur J Haematol; 2007 Mar; 78(3):227-34. PubMed ID: 17253972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
    Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
    In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
    Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
    Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
    Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population.
    Udupa CBK; Udupa KS; Pai A; Sherigar P
    Iran J Pathol; 2020; 15(3):182-188. PubMed ID: 32754213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
    Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
    Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.
    Gupta R; Kaur G; Kumar L; Rani L; Mathur N; Sharma A; Dahiya M; Shekhar V; Khan S; Mookerjee A; Sharma OD
    Ann Hematol; 2018 Dec; 97(12):2447-2454. PubMed ID: 30056581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.